Who is eligible for clinical trial NCT07612878?

Participants must meet protocol criteria for COPD (Chronic Obstructive Pulmonary Disease). Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07612878 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-27

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry (NCT07612878)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Sanofi

🩺 Plain-English Summary (8th-Grade Level)

The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (4 items).

Location: IU Health Pulmonology & Critical Care Medicine — Indianapolis, Indiana

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

COPD patients who are newly referred to start dupilumab treatment
Age ≥ 40 years
Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI)
Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments
Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (3 Sites)

IU Health Pulmonology & Critical Care Medicine — Indianapolis, Indiana
Duke — Durham, North Carolina
The Lung & Sleep Institute of North Texas — North Richland Hills, Texas

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗